From that gene set we chose two genes, SATB1 and LMNA, for further assessment as potential biomarkers of high-risk prostate cancer because both genes repositioned in a single high-risk T3 stage cancer, but not in two intermediate risk T2 cancers, or a low risk T2 cancer (Leshner et al., 2016). This evidence concerns the gene SATB1 and prostate cancer.